NCT06555081

A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants

Bioequivalence of Ruxolitinib XR Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 168 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is conducted to determine the Bioequivalence of Ruxolitinib XR 55 mg Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Ruxolitinib IR	Tablet
DRUG	Ruxolitinib XR	Tablet

Timeline

• Start date: 2024-09-25
• Primary completion: 2024-10-25
• Completion: 2024-11-07
• First posted: 2024-08-15
• Last updated: 2025-02-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study